Ryan Jacobs, MD MS

Husband. General Surgery Resident @NMSurgery

[Nidhi Reddy, MD @nidhikreddy]

Congratulations to all our amazing resident and fellow educators!!

@NMSurgery

[Nidhi Reddy, MD @nidhikreddy]

@RyanJacobsMD presented an amazing summary of his 2 years of work as a 2026 Kanavel Surgical Scholar Award Winner!
@NMSurgery

[CU Anschutz Department of Surgery @CUDeptSurg]

We are so excited to announce our 2027-2030 Cardiothoracic Surgery Fellows, Jake Cotton, MD, and Ryan Jacobs, MD! 🥼🌟

[Ryan Jacobs, MD MS @RyanJacobsMD]

Thrilled to share I will be joining the team at @CUDeptSurg for Thoracic Surgery fellowship. Excited to get to work!

[CU Anschutz Department of Surgery @CUDeptSurg]

We are so excited to announce our 2027-2030 Cardiothoracic Surgery Fellows, Jake Cotton, MD, and Ryan Jacobs, MD! 🥼🌟

[Northwestern Surgery @NMSurgery]

Incredibly humbled to hear from @JosephSakran for the 2nd Annual #HealthEquity Grand Rounds. He met with trainees and discussed further the ways surgeons can engage in their work meaningfully by building their clinical content expertise and adding advocacy and passion work.

[gilberto lopes @GlopesMd]

Top lung cancer developments in 2025?

My take:
2025 wasn’t about a single disruptive moment. It was about consolidation, maturation, and a few long-awaited signals finally turning solid.

1) MARIPOSA delivers OS
Amivantamab + lazertinib demonstrates an overall survival benefit over osimertinib in first-line EGFR-mutant NSCLC. Toxicity, logistics, and sequencing still matter—but this is now a real OS-based conversation, not just a PFS debate.

2) FLAURA2 confirms upfront intensification can matter
Osimertinib + chemotherapy shows improved OS vs osimertinib alone. Reinforces that combination strategies can deepen benefit, at the cost of complexity and tolerability. “Best first-line EGFR strategy” is now legitimately plural.

3) HER2 finally matters clinically
Accelerated approvals for zongertinib and sevabertinib in HER2-mutant NSCLC. Oral TKIs, meaningful response rates, and a credible path beyond antibody-drug conjugates alone.

4) EGFR exon 20 keeps inching forward
Sunvozertinib approved post-platinum. Incremental progress, but still meaningful in a historically difficult molecular subset.

5) c-MET ADC enters routine practice
Telisotuzumab vedotin approved for MET-high NSCLC. Expression-based biomarkers and ADCs are now firmly embedded in lung cancer decision-making.

6) A genuine advance in SCLC
Tarlatamab converts to full approval in platinum-refractory ES-SCLC with a survival benefit. Rare, and important.

7) Companion diagnostics become unavoidable
HER2 TKD, EGFR exon 20, MET expression—therapy is increasingly inseparable from the assay used to define eligibility. Testing strategy is now a core clinical decision.

8) Combination immunotherapy reality check
ATR inhibition + durvalumab misses OS (LATIFY). A reminder that biological plausibility still has to survive Phase 3.

9) AI moves from novelty to infrastructure
Improved CT nodule detection, risk stratification, and workflow support. Still assistive, not autonomous—but no longer theoretical.

10) Direction of travel is clear
More rare targets, more ADCs, OS gains in EGFR-mutant disease, slow but meaningful progress in SCLC—and increasing pressure on systems to deliver precision care at scale.

Bottom line: 2025 didn’t reinvent lung cancer. It made several long-promised ideas finally defensible at the OS level. That’s quieter progress—but it’s the kind that lasts.

#LCSM @SylvesterCancer @IASLC @myESMO @lungoncdoc @Latinamd @COlazagasti @Jani_Chinmay @NarjustFlorezMD @DrJNaidoo @StephenVLiu @EddieSantosMD @RManochakian @LuisRaezMD @uicc

[Brian Lawenda MD @BLawenda]

When my mother was choosing between lobectomy and SBRT for a small lung cancer, the real question wasn’t which treatment was “better,” it was which one would preserve the life she worked so hard to maintain.
Her decision hinged on the quality of her life after treatment.
When two well-validated options offer similar chances of cancer control, the conversation naturally shifts to what matters most: independence, mobility, and the ability to keep living the life a patient values.
For her, the choice became unmistakably clear.
🔗 https://t.co/jKWytFCNSw

[Ryan Jacobs, MD MS @RyanJacobsMD]

Had a great time presenting our #NLP work at @SurgOutcomes Annual Meeting as a #ZinnerFellow and #qualitativeresearch at #ACSCC2025 over the past few days

[Adam B. Weiner, MD @Adam_Weiner535]

The hardest lessons after training aren’t always in the OR or clinic.

🙏 I wrote this essay for anyone navigating their first year as an attending.

“Unseen Scars” in @JAMA_current

🔗https://t.co/0e09Zx1nb6

[Annals of Surgical Oncology @AnnSurgOncol]

September Issue: Outcomes After Resection of #Adenocarcinoma of the #GastricCardia by Surgical Approach @David_Bentrem @RyanJacobsMD @liggett_md

https://t.co/0pw1WcymdM

@cchildersmd
@SyedAAhmad5

[Karen J. Ho, MD @karenholab]

So excited for the 6th Annual William H. Pearce, MD Research Symposium tomorrow, showcasing the research done by our amazing trainees this year, a talk by Edelstone-Bendix Visiting Professor @laparoscopes, and the graduating chiefs residents!

[Northwestern Surgery @NMSurgery]

Join us Thursday, June 12 at 9am for the @NMSurgery Research Conference INSIGHT Presentations. We'll hear from Daniel Liesman, MD, Nicole Ontiveros, MD and @John_B_Rode. All moderated by @LaraLopesMD.

[Dr Amol Akhade @SuyogCancer]

Landmark OS data from #CheckMate816 just dropped in @NEJM!
🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers:
✅ 5-yr OS: 65.4% vs 55.0%
✅ HR: 0.72 (p=0.048)
✅ Lung cancer–specific survival HR: 0.65
✅ OS with pCR: 95.3%
✅ ctDNA clearers: 75%+ OS
📌 No lung cancer deaths in pCR patients
#LungCancer #Immunotherapy #ASCO25 #Oncology @FordePatrick @asco @OncoAlert

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[Charles Jiang MD, MPH @CharlesJiangMD]

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[LARVOL @Larvol]

As we are heading for the @ASCO-2025, here's a preview of top lung cancer trials, most discussed among oncologists on X, highlighted by @Larvol CLIN.

Get the latest #ASCO25 updates: https://t.co/051z3BNE4z

#LARVOL #LungCancer #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights | @Larvol | @ADesaiMD | @HerediaOncologo | @HHorinouchi | @DrRiyazShah | @FordePatrick | @Latinamd | @Tony_Calles | @lungoncdoc | @LindaMThoracic | @BrendonStilesMD

[Hidehito HORINOUCHI @HHorinouchi]

☑️#ASCO25 Abstract🆙
☑️#LCSM Oral, LocReg/SCLC
🔥NeoADAURA: Neoadjuvant osimertinib ± chemotherapy (CT) vs CT alone in resectable epidermal growth factor receptor-mutated NSCLC
🎙️ @ChaftJamie
🎯Osi+CT / Osi / PBO+CT: MPR 26%/25%/2%, pCR 4%/9%/0%
@OncoAlert @ASCO
https://t.co/iiYuG71esy

[Patrick Forde @FordePatrick]

Remarkable results for neoadj chemo-immunotherapy in locally advanced, N2/N3, lung cancer. 75% curative resections w v high pCR. Notably >40% of pts treated had high PD-L1 (unselected would be ~25-30%) but the boundary for lung surgery continues to chase the horizon #LCSM

[Dr Amol Akhade @SuyogCancer]

🔥 Final analysis: CheckMate 577
Adjuvant nivolumab in resected stage II/III EC/GEJC post-CRT & surgery
✅ DFS benefit maintained
21.8 vs 10.8 mo
HR 0.76 (95% CI 0.63–0.91)
🧠 DMFS improved
27.3 vs 14.6 mo
HR 0.75 (95% CI 0.62–0.90)
⚠️ OS not statistically significant
51.7 vs 35.3 mo
HR 0.85; P = 0.1064
Grade 3–4 TRAEs: 14% vs 7%
Discontinuation: 5% vs 3%
#Immunotherapy #GIcancer #CheckMate577 #ASCO25 #OncoTwitter @ASCO @NiuSanford @GIcancerDoc @OncoAlert